文献速递银屑病与炎症性皮肤病

生物制剂与银屑病患者银屑病关节炎风险:系统综述与荟萃分析

Biologic therapies and psoriatic arthritis risk in psoriasis: A systematic review and meta-analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-06-02

总体分析未发现生物制剂与非生物制剂在预防PsA方面有显著差异(RR 0.71,95%CI 0.34-1.51)。亚组分析提示不同生物制剂类别风险可能不同,但证据主要来自回顾性队列研究,需前瞻性研究验证。

要点

  • 生物制剂整体未显著降低银屑病患者PsA发生风险(RR 0.71,95%CI 0.34-1.51)。
  • 临床队列研究中生物制剂组PsA风险较低(RR 0.31,95%CI 0.11-0.87),注册研究未见差异。
  • 部分分析提示IL-17i、IL-23i或IL-12/23i较TNFi与更低PsA风险相关。

核心结论

  • 生物制剂整体与银屑病患者PsA风险降低无显著关联,但按数据来源和生物制剂类别的亚组分析提示可能的风险修饰作用。

研究设计与样本

  • 主要终点为银屑病患者PsA发病率,次要终点为PsA发生的风险比(HR),采用随机效应模型计算汇总RR和HR。

主要发现

  • 主要分析显示bDMARDs与非生物制剂在预防PsA方面无显著差异(RR 0.71,95%CI 0.34-1.51;HR 0.71,95%CI 0.44-1.17)。
  • 按数据来源亚组分析:临床队列研究中bDMARDs与较低PsA风险相关(RR 0.31,95%CI 0.11-0.87),注册研究未见差异(RR 1.03,95%CI 0.44-2.40)。
  • 排除一项影响性研究的敏感性分析中,接受bDMARDs的患者观察到较低PsA风险。
  • 报告二分类结局的研究中,IL-17i、IL-23i或IL-12/23i治疗较TNFi与更低PsA风险相关;IL-17i较IL-12/23i风险数值上更低。
  • 报告连续结局的研究中,IL-23i暴露较IL-17i或TNFi与更低PsA风险相关;IL-17i或IL-12/23i较TNFi与更低PsA风险相关。

临床怎么用

  • 生物制剂可能改变银屑病向PsA进展的轨迹,但当前证据不足以支持仅以预防PsA为目的使用生物制剂。
  • 治疗决策应继续基于银屑病严重度和患者个体风险因素进行个体化制定。

局限性

  • 多数数据来自回顾性队列研究,限制因果推断能力。
  • 研究结果属于假设生成性质,需前瞻性研究和随机试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether biologic therapies can potentially reduce the risk of transition to psoriatic arthritis (PsA) remains uncertain. OBJECTIVES: To evaluate whether biologic therapy is associated with a reduced risk of incident PsA among patients with psoriasis. METHODS: The primary and secondary endpoints were the incidence of PsA among patients with psoriasis and the associated hazard ratio (HR) for PsA development. Pooled relative risk (RR) and HR estimates were calculated using random effect models. RESULTS: Eighteen studies were included, involving conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDS (bDMARDs), phototherapy, topical therapy and no therapy. The primary analysis showed no significant difference between bDMARDs and non-biologic therapies in preventing PsA (RR: 0.71, 95% CI: 0.34, 1.51; HR: 0.71, 95% CI: 0.44, 1.17). Subgroup analyses by data source showed that a lower risk of incident PsA with bDMARDs was observed in clinical cohort studies (RR: 0.31, 95% CI: 0.11, 0.87), but not in registry studies (RR: 1.03, 95% CI: 0.44, 2.40). In sensitivity analyses excluding one influential study, a lower observed risk of PsA was identified among patients receiving bDMARDs. Among studies reporting dichotomous outcomes, treatment with interleukin-17 inhibitors (IL-17i), IL-23i or IL-12/-23i was associated with a lower risk of PsA compared with tumour necrosis factor inhibitors (TNFi). IL-17i also showed a numerically lower risk than IL-12/-23i. Among studies reporting continuous outcomes, IL-23i exposure was associated with a lower risk of PsA compared with IL-17i or TNFi. Similarly, IL-17i or IL-12/-23i was associated with a lower risk of PsA relative to TNFi. CONCLUSIONS: Biologic agent was not associated with a reduced overall risk of PsA in psoriasis, but subgroup analyses by data source and biologic class suggested potential risk modification. These findings are hypothesis-generating and require confirmation in prospective studies and randomized trials. Approximately one‐third of individuals with psoriasis will eventually progress to psoriatic arthritis. This review synthesizes evidence from international cohort studies across Europe, North America and Asia to evaluate whether biologic therapies for psoriasis are associated with a reduced risk of developing psoriatic arthritis. We conducted a systematic review and meta‐analysis of observational studies that followed adults with psoriasis without baseline joint symptoms, comparing biologic users with recipients of non‐biologic treatments. Across the available evidence, several biologic classes, particularly interleukin‐23 and interleukin‐17 inhibitors, were consistently associated with a lower observed risk of progression to psoriatic arthritis. However, most data derive from retrospective cohort studies, limiting the ability to draw causal inferences. Biologic therapies may modify the trajectory from cutaneous psoriasis to psoriatic arthritis, but current evidence is insufficient to justify their use solely for preventive purposes. Treatment decisions should continue to be individualized based on psoriasis severity and patient‐specific risk factors. More robust prospective studies are required to determine whether particular biologic pathways confer true preventive benefit.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Yang L, Gao X, Wang Z, et al. Biologic therapies and psoriatic arthritis risk in psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2026. PMID: 42227826. doi:10.1111/jdv.70540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。